Cipla Q4 FY26: Record Revenue, Margin Reset, and a US Respiratory Inflection Point

Cipla closed FY26 with its highest ever annual revenue, but the year also marked a clear margin reset. Consolidated revenue for Q4 FY26 stood at INR 6,541 crore, while EBITDA came in at INR 997 crore, translating to a 15.2% margin. Profit after tax attributable to shareholders was INR 555 crore, or an 8.5% margin.

For the full year, revenue rose to INR 28,163 crore versus INR 27,548 crore in FY25. However, profitability declined meaningfully. EBITDA fell to INR 5,925 crore (21.0% margin) from INR 7,128 crore (25.9% margin) in FY25. PAT declined to INR 3,879 crore (13.8% margin) from INR 5,273 crore (19.1% margin). R&D spending remained elevated at INR 1,974 crore, which is 7.0% of revenue.

Behind these numbers is a company that is simultaneously defending a large India franchise, scaling Africa and EMEU, and attempting to shift the US business toward complex respiratory and other differentiated assets. The call also made it clear that FY27 will be a transition year for margins, with management guiding to 18.5% to 20% EBITDA margin for the year, and improvement weighted to the second half.

A diversified revenue base, with India still the anchor

Cipla’s Q4 revenue mix underscores the company’s reliance on India, while also showing meaningful scale in the US and Africa. In Q4 FY26, One India contributed 46% of revenue, followed by North America at 22%, One Africa at 19%, Emerging Markets and Europe at 12%, and API and others at 1%.

On an annual basis, One India remained the largest business at 45% of FY26 revenue, with North America at 24%, One Africa at 15%, Emerging Markets and Europe at 13%, API at 2%, and others at 1%.

India: chronic mix and launches remain the core narrative

The India business delivered INR 3,007 crore in Q4 FY26, growing 15% year-on-year. For FY26, One India revenue was INR 12,680 crore, growing 9% year-on-year. Management attributed the quarterly performance to double-digit growth across Branded Prescription, Trade Generics, and Consumer Health.

In branded prescriptions, Cipla highlighted its chronic mix at 60.2% and reiterated leadership in respiratory. Foracort crossed the INR 1,000 crore milestone in the Indian pharma market. Dytor scaled to over INR 650 crore. The company also emphasized breadth, citing 33 brands with revenue above INR 100 crore and 23 brands within the top 300 of the Indian pharma market.

Cipla also used the year to deepen its portfolio through launches and partnerships. The deck highlighted introductions across respiratory, antimicrobial resistance, urology, anti-diabetes, and dermatology. On partnerships, the company cited rights to distribute and promote Yurpeak in India, a partnership to launch Afrezza, and exclusive marketing and distribution rights for select Pfizer brands. It also cited the acquisition of a 100% stake in Inzpera Healthcare.

Consumer health remained a visible profit pool. The presentation disclosed FY26 consumer brands revenue in India at INR 1,690 crore and highlighted Nicotex, Omnigel and CiplaDine as leadership brands.

North America: Ventolin approval from the US facility changes the conversation

North America revenue stood at USD 155 million in Q4 FY26 and USD 780 million for FY26. Management described the approval of the first AB-rated generic Ventolin with competitive generic therapy as a strategic inflection point, given it is the first commercial MDI product to be manufactured from the company’s US facility.

The company expects to launch the product in the coming months and indicated that the ramp-up will be more visible in the second half of FY27. Management also stated that Cipla will be exclusive for six months for this product.

Cipla’s medium-term US strategy is anchored in a broader complex pipeline. The presentation highlighted respiratory filings, peptides and complex generics, and differentiated products including 505(b)(2) and oligonucleotides. Management stated it is targeting around 40 to 50 product filings over the next three years, including 12 first-to-file opportunities and eight B2 opportunities. The deck noted five respiratory assets filed, four expected commercialization in FY27, and additional assets to be filed over the next 24 months, including two with green propellant.

This pipeline-driven view also shaped the company’s US ambition. Management clarified it is targeting a USD 1 billion exit run-rate by the end of FY27, rather than USD 1 billion revenue within FY27.

Africa, EMEU and balance sheet: scale plus resilience

One Africa grew 14% year-on-year in Q4 FY26 to USD 135 million and delivered USD 483 million for FY26. Cipla highlighted that in South Africa, its secondary growth outpaced market growth, and it provided market segment data showing rank and share across prescription, OTC, and overall categories.

Emerging Markets and Europe crossed USD 400 million in FY26, with the company highlighting resilience amid volatility and war-related uncertainty.

Cipla’s balance sheet remained a key support pillar. Cash and cash equivalents were INR 11,140 crore as of March 2026, while total debt including lease liabilities stood at INR 614 crore. Management described the company as having over USD 1 billion net cash, positioning it to fund R&D and selective inorganic opportunities.

FY27: margins guided lower, but with a second-half recovery setup

The core forward-looking disclosure was the FY27 EBITDA margin guidance of 18.5% to 20%, with sequential improvement and the key improvement expected in the second half. Management linked near-term margin restraint to elevated people and R&D investments, which it expects to be leveraged as new launches scale.

Importantly, the guidance excludes Lanreotide. Management said the partner is working on remediation efforts and it expects better visibility in the next quarter, including around a potential FDA reinspection.

The FY27 setup therefore looks like a transition: India is expected to sustain momentum with a chronic tilt, while the US outcome hinges on the timing and commercial ramp-up of respiratory approvals and launches. The company’s stated guidance suggests that if the second half plays out as intended, profitability should move closer to the company’s longer-term target of sustaining margins above 20%.

In summary, Cipla’s FY26 was defined by record revenue but lower profitability. The investment cycle in people and complex R&D is visible in margins today, and management is positioning FY27 as the year when that investment begins translating into scale, especially in the US respiratory franchise.